Fatigue in rheumatoid arthritis: Quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS study

Clinical and Experimental Rheumatology

Volumn 33, Issue 5, 2015, Pages 664-670

  Gossec, Laure ^a,b   Steinberg, Ghislaine ^c   Rouanet, Stephanie ^d   Combe, Bernard ^e,f  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Medical Department   (France)

^d eXYSTAT   (France)

^e LAPEYRONIE HOSPITAL   (France)

^f UNIV MONTPELLIER   (France)

Author keywords

FACIT; Fatigue; Outcomes research; Patient perspective; Quality of life; Response criteria; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FACIT FATIGUE SCALE; FATIGUE; FEMALE; FRANCE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE QUESTIONNAIRE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT ACCEPTABLE SYMPTOM STATE QUESTIONNAIRE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHEUMATOID ARTHRITIS; VISUAL ANALOG SCALE; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHOLOGY; REMISSION; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FRANCE; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84944391205     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. KIRWAN J, HEWLETT S, HEIDBERG T et al.: Incorporating the patient perspective into outcome assessment in rheumatoid arthritis-progress at Omeract 7. J Rheumatol 2005; 32: 2250-6.
2. HEWLETT S, COCKSHOTT Z, BYRON M et al.: Patients' perception of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005; 53: 697-702.
3. GOSSEC L, DOUGADOS M, RINCHEVAL N et al.: Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009; 68: 1680-5.
4. MINNOCK P, KIRWAN J, BRESNIHAN B: Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1533-6.
5. CHAUFFIER K, SALLIOT C, BERENBAUM F, SELLAM J: Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford) 2012; 51: 60-8.
6. NICKLIN J, CRAMP F, KIRWAN J, URBAN M, HEWLETT S: Collaboration with patients in the design if patient-reported outcome measures: capturing the experience of fatigue in rheumatoid arthritis. Arthritis Care Res 2010, 62: 1552-8.
7. STAMM T, CIEZA A, COENEN M et al.: Validating the International Classification of Functioning, Disability and Health Comprehensive Core Set for Rheumatoid Arthritis From the Patient Perspective: A Qualitative Study. Arthritis Rheum 2005; 53: 431-9.
8. CARR A, HEWLETT S, HUGHES R et al.: Rheumatology Outcomes: The Patient's Perspective. J Rheumatol 2003; 30; 880-3.
9. NIKOLAUS S, BODE C, TAAL, VAN DER LAAR MA: Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2013; 65: 1128-46.
10. POLLARD LC, CHOY EH, GONZALEZ J, KHOSHABA B, SCOTT DL: Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford) 2006; 45: 885-9.
11. STAUD R: Peripheral and central mechanisms of fatigue in inflammatory and noninflammatory rheumatic diseases. Curr Rheumatol Rep 2012; 14: 539-48.
12. NICASSIO PM, ORMSETH SR, CUSTODIO MK, IRWIN MR, OLMSTEAD R, WEISMAN MH: A multidimensional model of fatigue in patients with rheumatoid arthritis. J Rheumatol 2012; 39: 1807-13.
13. SMOLEN J, BEAULIEU A, RUBBERT-ROTH A et al.: Effect of interleukin 6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomized trial. Lancet 2008; 371: 987-97.
14. EMERY P, KEYSTONE E, TONY HP et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial.(The RADIATE study). Ann Rheum Dis 2008; 67: 1516-23.
15. GENOVESE M, McKAY J, NASONOV: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. (The TOWARD Study). Arthritis Rheum 2008; 58: 2968-80.
16. JONES G, SEBBA A, GU J et al.: The AMBITION study: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis. Ann Rheum Dis 2010; 69: 88-96.
17. KREMER JM, FLEISCHMANN RM, HALLAND AM et al.: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-21.
18. PINCUS T, YACIZI Y, SOKKA T: Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol 2007; 21: 601-28.
19. CELLA D, YOUNT S, SORENSEN M, CHARTASH E, SENGUPTA N, GROBER J: Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 811-9.
20. http://www.facit.org.Accessed on Nov 16, 2014.
21. TUBACH F, RAVAUD P, MARTIN-MOLA E et al.: Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: results from a prospective multinational study. Arthritis Care Res (Hoboken) 2012; 64: 1699-707.
22. WOLFE F: Fatigue Assessments in Rheumatoid Arthritis: Comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004; 31: 1896-902.
23. PREVOO ML, van 't HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
24. BRUCE B, FRIES JF: The Stanford Health Assessment Questionnaire: Dimensions and Practical Applications. Health Qual Life Outcomes 2003; 1: 20-5.
25. ZIGMOND AS, SNAITH RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
26. STANLEY B, COHEN SB, EMERY P et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 2793-806.
27. YOUNT S, SORENSEN MV, CELLA D, SENGUPTA N, GROBER J, CHARTASH EK: Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 838-46.
28. STRAND V, MEASE P, BURMESTER GR et al.: Rapid and sustained improvements in healthrelated quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 2009; 11: R170.
29. HIFINGER M, PUTRIK P, RAMIRO S et al.: In addition to individual demographic ad clinical measures, levels of fatigue are dependent on country of residence. An analysis among 3920 patients from 17 countries (THE COMORA STUDY). Ann Rheum Dis 2014; 73 (Suppl. 2) [FRI0082].
30. NICKLIN J, CRAMP F, KIRWAN J, GREENWOOD R, URBAN M, HEWLETT S: Measuring Fatigue in Rheumatoid Arthritis: A CrossSectional Study to Evaluate the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire, Visual Analog Scales, and Numerical Rating Scales. Arthritis Care Res 2010; 62: 1559-68.
31. STRAND V, BURMESTER G, OGALE S, DEVENPORT J, JOHN A, EMERY P: Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factors inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford) 2012; 51: 1860-9.
32. BURMESTER G, FEIST E, KELLNER H, BRAUN J, IKING-KONERT C, RUBBERT-ROTH A: Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011; 70: 755-9.
33. De CROON EM, SLUITER JK, KAMMEIJER M et al.: Work ability of Dutch employees with rheumatoid arthritis. Scand J Rheumatol 2005; 34: 277-83.
34. HAZES JM, TAYLOR P, STRAND V, PORCARU O, COTEUR G, MEASE P: Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford) 2010; 49: 1900-10.
35. KHAN NA, SPENCER HJ, ABDA E et al.: Determinants of discordance in patients' and physicians' rating of Rheumatoid Arthritis disease activity. Arthritis Care Res (Hoboken) 2012; 64: 206-14.
36. HEWLETT S, CHALDER T, CHOY E et al.: Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology (Oxford) 2011; 50: 1004-6.
37. TREHARNE GJ, LYONS AC, HALE ED, GOODCHILD CE, BOOTH DA, KITAS GD: Predictors of fatigue over 1 year among people with rheumatoid arthritis. Psychol Health Med 2008; 13: 494-504.
38. JUMP RL, FIFIELD J, TENNEN H, REISINE S, GIULIANO AJ: History of affective disorder and the experience of fatigue in rheumatoid arthritis. Arthritis Care Res 2004; 51: 239-45.
39. WOLFE F, MICHAUD K: Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum 2009; 61: 667-73.
40. HEWLETT S, AMBLER N, ALMEIDA C et al.: Self-management of fatigue in rheumatoid arthritis: a randomised controlled trial of group cognitive-behavioural therapy. Ann Rheum Dis 2011; 70: 1060-7.